ALX Oncology Holdings Inc reports results for the quarter ended December 31 - Earnings Summary

ALX Oncology Holdings

06/03/2025 21:21

ALX Oncology Holdings Inc ALXO.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -93 cents.  The mean expectation of seven analysts for the quarter was for a loss of 67 cents per share. Wall Street expected results to range from -81 cents to -57 cents per share.

Reported revenue was zero​; analysts expected zero.

ALX Oncology Holdings Inc's reported EPS for the quarter was a loss of 55 cents​.

The company reported a quarterly loss of $29.16 million.

ALX Oncology Holdings Inc shares had fallen by 37.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for ALX Oncology Holdings Inc is $3.50

This summary was machine generated from LSEG data March 6 at 09:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.67
-0.55
Beat
Sep. 30 2024
-0.78
-0.58
Beat
Jun. 30 2024
-0.77
-0.76
Beat
Mar. 31 2024
-0.84
-0.71
Beat